Cellular uptake and concentrations of tamoxifen upon administration in poly(ε-caprolactone) nanoparticles

Jain RK. Delivery of molecular medicine to solid tumors. Science. 1996;271:1079–1080.

Jain RK. Delivery of molecular and cellular medicine in solid tumors. J Controlled Rel. 1998;53:49–67.

Au JLS, Jang SH, Zheng J, et al. Determinants of drug delivery and transport in solid tumors. J Controlled Rel. 2001;74:31–46.

Jain RK. Determinants of tumor blood flow: a review. Cancer Res. 1988;48:2641–2658.

Hobbs SK, Monsky WL, Yuan F et al. Regulation of transport pathways in tumor vessels: role of tumor type and microen vironment. Proc Natl Acad Sci U S A. 1998;95:4607–4612.

Lerner JL, Jordan VC. Development of antiestrogens and their use in breast cancer: Eight Cain memorial award lecture. Cancer Res. 1990;50:4177–4189.

MacGregor JI, Jordan VC. Basic guide to the mechanisms of antiestrogen action. Pharmacol Revs. 1998;50:151–196.

Jordan VC. Targeted antiestrogens to prevent breast cancer. Trends Endocrin Metab. 1999;10:312–317.

Hortobagyi G. Adjuvant therapy for breast cancer. Annu Rev Med. 2000;51:377–392.

Cameron DA, Richie AA, Langdon S, Anderson TJ, Miller WR. Tamoxifen induced apoptosis in ZR-75 breast cancer xenografts antedated tumour regression. Breast Cancer Res Treat. 1997;45:99–107.

Ruohola JK, Valve EM, Karkkainen MJ, Joukov V, Alitalo K, Harkonen PL. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol Cell Endocrinol. 1999;149:29–40.

Jordan VC. Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer. Annu Rev Pharmacol Toxicol. 1995;35:195–211.

Johnston SR. Acquired tamoxifen resistance in human breast cancer-potential mechanisms and clinical implications. Anticancer Drugs. 1997;8:911–930.

Seymour LW. Passive tumor targeting of soluble macromolecules and drug conjugates. Crit Rev Ther Drug Carrier Syst. 1992;9:135–187.

Duncan R, Sat Y-N. Tumor targeting by enhanced permeability and retention (EPR) effect. Ann Oncol. 1998;9:39–50.

Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Controlled Rel. 2000;65:271–284.

Nomura T, Koreeda N, Yamashita F, Takakura Y, Hashida M. Effect of particle size and charge on the disposition of lipid carriers after in tratumoral injection into tissue-isolated tumors. Pharm Res. 1998;15:128–132.

Monsky WL, Fukumura D, Gohongi T, et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res. 1999;59:4129–4135.

Juliano R. Selective endocytosis of macromolecular drug carriers. In: Robinson JR, Lee VH, eds. Controlled Drug Delivery. 2nd ed. New York, NY: Marcel Dekker Inc; 1987:582–621.

Chawla JS, Amiji MM. Biodegradable poly (ε-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. Int J Pharm. 2002;249:127–138.

Astier BD, Ferrer MJ, Benoit G, Fleury J, Rolland A, Leverge R. Enhancement of adriamycin antitumor activity by its binding with an intracellular sustained release form, polymethymethacrylate nanospheres, in U-937 cells. Cancer Res. 1988;48:1835–1841.